Additionally, KRAS mutations were explored together with mNDRG4, methylated tissue factor pathway inhibitor 2 (mTFPI2), and mSDC2 in an mt-DNA assay which exceeded FOBT in detecting stage I-III CRC [63]. The gene discussed is KRAS; the disease is colorectal carcinoma.